Critical Path Institute – 2024 Breakthrough Research and Innovation in Drug Development Grant (BRIDGe)

The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
Projects eligible for TRxA BRIDGe awards include early lead optimization and IND-enabling studies, using small molecule approaches. Biologicals, including peptides or antibodies, oligonucleotides, cell and gene therapy applications and medical devices are not eligible at this time. Drug repurposing approaches are also not eligible during this funding cycle.

Duration:      1 year

Funding:        Three levels: $250,000, $500,000, and $1,000,000

Eligibility: There are no geographical restrictions for grantees, although applicants must be faculty members at a university or non-profit research institution. Ownership rights to the program must reside at a university or not-for-profit research institution.

How to Apply: Pre-proposal applications should be submitted online through the dedicated grant portal. Please note that C-path is expecting non-confidential pre-proposal. You’ll find a sample pre-proposal here. An institutional support letter will be required for the proposal submission, please reach out to the Research Office.
Successful proposals will be notified the week of 13 May 2024.

Application Deadline: 31 March 2024

Further information

• More information about the award is available here.
• The online application can be found here.
• Please get in touch with the Research Office to obtain a letter of support, which will be needed at the time of full proposal submission.
• For any other questions, please contact the Research Office.